These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20073450)

  • 21. Imatinib mesylate causes hypopigmentation in the skin.
    Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
    Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy].
    Sumi M; Tauchi T; Shimamoto T; Sshida G; Nakajima A; Ito Y; Ohyashiki K
    Rinsho Ketsueki; 2002 Sep; 43(9):868-70. PubMed ID: 12412295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
    Cortes J; O'Brien S; Quintas A; Giles F; Shan J; Rios MB; Talpaz M; Kantarjian H
    Cancer; 2004 Jun; 100(11):2396-402. PubMed ID: 15160343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia.
    Kawakami T; Kawanabe T; Soma Y
    Acta Derm Venereol; 2009; 89(3):325-6. PubMed ID: 19479144
    [No Abstract]   [Full Text] [Related]  

  • 25. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
    Chang H; Shih LY
    Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
    Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
    Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
    Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
    Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
    Breccia M; D'Elia GM; D'Andrea M; Latagliata R; Alimena G
    Eur J Haematol; 2005 Jan; 74(1):89-90. PubMed ID: 15613116
    [No Abstract]   [Full Text] [Related]  

  • 29. [Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia].
    Yamaguchi M; Konishi I
    Rinsho Ketsueki; 2003 Apr; 44(4):254-6. PubMed ID: 12784659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(2):75-86. PubMed ID: 12122963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
    Deininger MW; Druker BJ
    Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
    Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
    [No Abstract]   [Full Text] [Related]  

  • 33. [Intestinal bleeding during the treatment of chronic myeloid leukemia with imatinib mesylate].
    Yokote T; Akioka T; Nakayama S; Oka S; Hara S; Yamano T; Tsuji M; Hanafusa T
    Rinsho Ketsueki; 2005 Sep; 46(9):1060-4. PubMed ID: 16440765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
    Zaucha JM; Wyrowinska E; Prejzner W; Calbecka M; Hellmann A
    Clin Lab Haematol; 2006 Jun; 28(3):208-10. PubMed ID: 16706939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
    Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
    Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
    [No Abstract]   [Full Text] [Related]  

  • 36. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.
    Ferraresi V; Catricalà C; Ciccarese M; Ferrari A; Zeuli M; Cognetti F
    Anticancer Res; 2006; 26(6C):4771-4. PubMed ID: 17214339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib.
    Cervetti G; Galimberti S; Fazzi R; Papineschi F; Azzarà A; Simi P; Petrini M
    Eur J Clin Invest; 2004 Mar; 34(3):243-4. PubMed ID: 15025685
    [No Abstract]   [Full Text] [Related]  

  • 38. [Imatinib-induced DRESS].
    Goldman J; Duval-Modeste AB; Lambert A; Contentin N; Courville P; Musette P; Joly P
    Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V; Vakalopoulou S; Tziomalos K
    Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
    [No Abstract]   [Full Text] [Related]  

  • 40. Imatinib mesylate-induced interstitial pneumonitis.
    Ma CX; Hobday TJ; Jett JR
    Mayo Clin Proc; 2003 Dec; 78(12):1578-9. PubMed ID: 14661689
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.